Coinfection with hepatitis C virus (HCV) does not adversely affect the outcomes from treatment with highly active antiretroviral therapy (HAART) for HIV, according to a presentation on July 6 at the XIV International AIDS Conference in Barcelona, Spain. Physicians should therefore treat coinfected patients as aggressively as those without HCV
infection, the investigators suggest. “In the U.S. and Europe, it is estimated that one in three of HIV-infected persons are also infected with hepatitis C and many of them are injection drug users,” Glen R. Hanson, Acting Director of the U.S. National Institute on Drug Abuse, says in a news release.
“Research needs to continue to determine best approaches to treating those who are coinfected with HIV and hepatitis C.” Between January 1995 and January 2001, 1,955 HIV-infected patients without an AIDS diagnosis enrolled in this study, including 873 patients (44.6%) with HCV seropositivity.
The latter group was older, more likely to be African-American and to have a history of intravenous drug abuse than those who were HCV seronegative.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!